Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...
BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback